Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Rodney Dawson

Showing results (51-60 of 94) with videos related to

Pageof 10
Sort By:
Pharmacogenetics and Genomics|February 17, 2025
Pharmacogenetics of plasma dolutegravir exposure during 1-month rifapentine/isoniazid treatment of latent tuberculosisNia Covington, Anne F Luetkemeyer, Marjorie Z Imperial, et al.
The European Respiratory Journal|February 5, 2021
Increased bactericidal activity but dose-limiting intolerability at 50 mg·kg<sup>-1</sup> rifampicinLindsey H M Te Brake, Veronique de Jager, Kim Narunsky, et al.
Tuberculosis (Edinburgh, Scotland)|July 20, 2011
Predominance of interleukin-22 over interleukin-17 at the site of disease in human tuberculosisKerryn Matthews, Katalin A Wilkinson, Barbara Kalsdorf, et al.
The Lancet. Respiratory Medicine|July 26, 2015
Burden of tuberculosis in intensive care units in Cape Town, South Africa, and assessment of the accuracy and effect on patient outcomes of the Xpert MTB/RIF test on tracheal aspirate samples for diagnosis of pulmonary tuberculosis: a prospective burden of disease study with a nested randomised controlled trialGregory L Calligaro, Grant Theron, Hoosain Khalfey, et al.
Acta Tropica|December 12, 2022
Building sustainable clinical trial sites in Sub-Saharan Africa through networking, infrastructure improvement, training and conducting clinical studies: The PanACEA approachAnna-Maria Mekota, Stephen H Gillespie, Michael Hoelscher, et al.
Cell Host & Microbe|April 4, 2017
Anaerobic Bacterial Fermentation Products Increase Tuberculosis Risk in Antiretroviral-Drug-Treated HIV PatientsLeopoldo N Segal, Jose C Clemente, Yonghua Li, et al.
BMC Pulmonary Medicine|August 16, 2019
Toxicity related to standard TB therapy for pulmonary tuberculosis and treatment outcomes in the REMoxTB study according to HIV statusConor D Tweed, Angela M Crook, Rodney Dawson, et al.
The Journal of Antimicrobial Chemotherapy|January 30, 2015
Early phase evaluation of SQ109 alone and in combination with rifampicin in pulmonary TB patientsNorbert Heinrich, Rodney Dawson, Jeannine du Bois, et al.
Plos One|March 31, 2010
Clinical utility of a commercial LAM-ELISA assay for TB diagnosis in HIV-infected patients using urine and sputum samplesKeertan Dheda, Virginia Davids, Laura Lenders, et al.
The Journal of Antimicrobial Chemotherapy|March 28, 2025
Population pharmacokinetics and exposure-response relationship of the antituberculosis drug BTZ-043Simon E Koele, Norbert Heinrich, Veronique R De Jager, et al.
Pageof 10

Showing results (51-60 of 94) with videos related to

Sort By:
Pageof 10
Pharmacogenetics and Genomics|February 17, 2025
Pharmacogenetics of plasma dolutegravir exposure during 1-month rifapentine/isoniazid treatment of latent tuberculosisNia Covington, Anne F Luetkemeyer, Marjorie Z Imperial, et al.
The European Respiratory Journal|February 5, 2021
Increased bactericidal activity but dose-limiting intolerability at 50 mg·kg<sup>-1</sup> rifampicinLindsey H M Te Brake, Veronique de Jager, Kim Narunsky, et al.
Tuberculosis (Edinburgh, Scotland)|July 20, 2011
Predominance of interleukin-22 over interleukin-17 at the site of disease in human tuberculosisKerryn Matthews, Katalin A Wilkinson, Barbara Kalsdorf, et al.
The Lancet. Respiratory Medicine|July 26, 2015
Burden of tuberculosis in intensive care units in Cape Town, South Africa, and assessment of the accuracy and effect on patient outcomes of the Xpert MTB/RIF test on tracheal aspirate samples for diagnosis of pulmonary tuberculosis: a prospective burden of disease study with a nested randomised controlled trialGregory L Calligaro, Grant Theron, Hoosain Khalfey, et al.
Acta Tropica|December 12, 2022
Building sustainable clinical trial sites in Sub-Saharan Africa through networking, infrastructure improvement, training and conducting clinical studies: The PanACEA approachAnna-Maria Mekota, Stephen H Gillespie, Michael Hoelscher, et al.
Cell Host & Microbe|April 4, 2017
Anaerobic Bacterial Fermentation Products Increase Tuberculosis Risk in Antiretroviral-Drug-Treated HIV PatientsLeopoldo N Segal, Jose C Clemente, Yonghua Li, et al.
BMC Pulmonary Medicine|August 16, 2019
Toxicity related to standard TB therapy for pulmonary tuberculosis and treatment outcomes in the REMoxTB study according to HIV statusConor D Tweed, Angela M Crook, Rodney Dawson, et al.
The Journal of Antimicrobial Chemotherapy|January 30, 2015
Early phase evaluation of SQ109 alone and in combination with rifampicin in pulmonary TB patientsNorbert Heinrich, Rodney Dawson, Jeannine du Bois, et al.
Plos One|March 31, 2010
Clinical utility of a commercial LAM-ELISA assay for TB diagnosis in HIV-infected patients using urine and sputum samplesKeertan Dheda, Virginia Davids, Laura Lenders, et al.
The Journal of Antimicrobial Chemotherapy|March 28, 2025
Population pharmacokinetics and exposure-response relationship of the antituberculosis drug BTZ-043Simon E Koele, Norbert Heinrich, Veronique R De Jager, et al.
Pageof 10